Advanced BioDesign

Lyon, France – 23rd of March 2026 — Advanced BioDesign, a biotechnology company developing first‑in‑class ALDH1 inhibitors for treatment‑resistant cancers, today released an update on the progress of its Early Access Program (EAP), the advancement of its ODYSSEY first‑in‑human clinical trial, and the participation of its clinical investigators in upcoming scientific conferences.

Strong performance of the Early Access Program

Open since early 2025, the Early Access Program has enabled physicians to treat five patients who were not eligible to participate in the ODYSSEY clinical study. All patients continued treatment beyond the three initial cycles, resulting in a 100% continuation rate over the past year. 

These results highlight the feasibility of using ABD‑3001 in real‑world settings and the sustained clinical benefit observed by treating physicians. 

ODYSSEY clinical trial progressing on schedule 

The company is pleased to report that its ODYSSEY Phase I first‑in‑human clinical trial evaluating ABD‑3001 in patients with relapsed/refractory acute myeloid leukemia (AML) or high‑risk myelodysplastic syndrome (MDS) is progressing according to the timeline. The next major milestone, the Safety Review Committee (SRC), is scheduled for late April, keeping the program aligned with its planned development trajectory. 

Upcoming scientific presentations by ODYSSEY investigators in Société Française d’Hématologie congress which will be held in Paris from 25^th to 27^th of March. 

Title: ODYSSEY: A first-in-human study of the aldehyde dehydrogenase (ALDH) inhibitor ABD-3001 in patients with refractory/relapsed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).

Several ODYSSEY clinical investigators will present new scientific results at upcoming international conferences: 

Oral Presentation – Pr. Régis Costello: “ALDH1 as a mediator of adaptive resistance to anthracyclines in acute myeloid leukemia.” This presentation will highlight the mechanistic role of ALDH1 in chemotherapy resistance and the rationale for targeting this pathway with ABD‑3001. 

Poster Presentation – ODYSSEY Clinical Trial Update: “ODYSSEY: Phase I first‑in‑human study of the aldehyde dehydrogenase (ALDH) inhibitor ABD‑3001 in patients with relapsed/refractory acute myeloid leukemia (AML) or high‑risk myelodysplastic syndrome (MDS).” The poster will provide new data and insights on safety, tolerability, and early signs of clinical activity. 

Commitment to innovation for patients with high unmet needs

Advanced BioDesign continues to accelerate the development of ABD‑3001, a first‑in‑class ALDH1 inhibitor designed to overcome cancer cell resistance mechanisms. The company remains committed to working closely with clinicians and regulatory bodies to bring new therapeutic options to patients who lack alternatives. 

***

About ABD-3001

ABD-3001 is the pharmacological form of DIMATE, a first-in-class « suicide » inhibitor of class 1 aldehyde dehydrogenases (ALDH1). This innovative molecule was developed to target a key survival mechanism of cancer cells. It works by blocking ALDH, which tumor cells often use to protect themselves from oxidative stress. By inhibiting this enzyme, DIMATE creates an internal imbalance that leads to cancer cell death, while largely sparing healthy cells. This approach aims to overcome resistance mechanisms to standard chemotherapy.

Currently being evaluated in a Phase 1 clinical trial, ODYSSEY, ABD-3001 could offer an innovative therapeutic option for patients with no remaining treatment alternatives.

About Acute Myeloid Leukemia

AML represents a $1.5 billion global market, with limited innovation in frontline and salvage settings. Despite the introduction of targeted therapies, anthracycline-based chemotherapy remains a backbone of treatment, and resistance continues to drive poor outcomes. By addressing a key resistance mechanism, Advanced BioDesign’s ALDH1-targeted approach has the potential to transform the standard of care, expand into combination regimens, and capture significant share in both relapsed/refractory and high-risk AML segments. Beyond AML, ALDH1 inhibition opens opportunities in solid tumors and other hematologic malignancies, creating a multi-billion-dollar market potential.

About Advanced BioDesign  

Advanced BioDesign is a clinicalstage biotechnology company committed to addressing one of the most critical challenges in oncology: treatment resistance and relapse, which continue to impact millions of cancer patients worldwide. The company has developed a first in class therapeutic approach targeting ALDH1, a key enzyme leveraged by cancer cells to detoxify harmful metabolic by-products and evade the effects of standard treatments. Unlike therapies focused on specific genetic mutations, Advanced BioDesign’s ALDH1 inhibitors act on a universal resistance mechanism shared across multiple tumor types. Its lead candidate, ABD3001, selectively disrupts cancer cell metabolism by inhibiting ALDH1, triggering apoptosis while sparing healthy cells—an innovative strategy designed to overcome chemoresistance. ABD3001 represents a major breakthrough in oncology, offering a novel, scalable, and mechanism-driven solution to treatment resistance. Supported by strategic partnerships, a pathway enabling rapid market entry, and a strong foundation in cellular biology, Advanced BioDesign is poised to redefine the standards of cancer therapy while delivering meaningful clinical and economic impact.

For more information: https://www.a-biodesign.com; LinkedIn @Advanced BioDesign   

For more information: https://www.xerys.com; LinkedIn @Xerys.  

Contacts:  

Advanced BioDesign 

Ismail Ceylan ismail.ceylan@a-biodesign.com